Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 94.23M +61.6% |
| Revenue (ttm) | 65,343 -70.0% |
| Net Income | -84.95M |
| EPS | -1.81 |
| Shares Out | 81.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 721,524 |
| Open | 1.150 |
| Previous Close | 1.140 |
| Day's Range | 1.115 - 1.160 |
| 52-Week Range | 1.030 - 2.979 |
| Beta | 1.70 |
| Analysts | Buy |
| Price Target | 6.75 (+486.96%) |
| Earnings Date | May 12, 2026 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i... [Read more]
Financial Performance
In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INO stock is "Buy." The 12-month stock price target is $6.75, which is an increase of 486.96% from the latest price.
News
INOVIO Announces Pricing of $17.5 Million Public Offering
PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
INOVIO to Participate in Upcoming Scientific Conference
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
Inovio Stock Up On Earnings, Pipeline Progress
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher on Friday morning after the company reported fourth-quarter results that topped Wall Street's loss estimate and highlighted progress ...
Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025
BLA for INO-3107 accepted by FDA with a PDUFA date of October 30, 2026, though eligibility for Accelerated Approval is under review. Cash runway extends into Q4 2026, with commercial launch preparations and pipeline partnerships advancing.
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U...
Inovio Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
INO-3107, a DNA medicine for RRP, is under FDA review with a PDUFA date in October and shows strong efficacy in reducing surgeries. Differentiation from competitors includes in-office administration and no need for surgeries during treatment. Commercial and regulatory preparations are well advanced.
INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of b...
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of b...
Inovio Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The discussion highlighted progress toward FDA approval for INO-3107, a DNA-based therapy for RRP, with strong clinical data showing reduced surgeries and a favorable safety profile. The company is focused on regulatory milestones, market opportunity, and advancing its pipeline through partnerships.
INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa. , Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
Inovio Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
INO-3107 demonstrated significant reduction in surgeries for RRP, with a strong safety profile and patient preference over competitors. The company is preparing for a potential mid-next-year FDA decision, expanding its pipeline, and advancing in vivo protein production technology.
INOVIO to Participate in December Investor Conferences
PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO Announces Pricing of $25 Million Public Offering
PLYMOUTH MEETING, Pa. , Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot...
Inovio Pharmaceuticals Earnings Call Transcript: Q3 2025
INO-3107 BLA submission completed with FDA acceptance expected by year-end and a potential mid-2026 launch. Operating expenses and loss from operations decreased year-over-year, with a cash runway into Q2 2026. INO-3107 is positioned as a differentiated, patient-centric RRP treatment.
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 ...
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy designat...
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
PLYMOUTH MEETING, Pa. , Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
PLYMOUTH MEETING, Pa. , Oct. 23, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as...
Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity...
Inovio Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
INO-3107 is advancing toward FDA submission as a first-in-class DNA medicine for RRP, showing strong, durable reductions in surgeries and a favorable safety profile. The pipeline includes next-generation DNA-encoded antibody and protein therapies, with commercial launch preparations underway.